The science is expensive. GRAIL was sent off from Illumina with a cash cushion to fund the journey.
↓ scroll to read
✦ The bottom line
GRAIL's 2025 operating loss was $562M — roughly four times its revenue — spent on huge clinical studies, lab operations, and R&D. It can sustain that because when Illumina spun GRAIL off in 2024, it sent the company out with a substantial cash reserve. The clock is multi-year, but it is ticking.
↓ the brief below
✦ Teach me
Funding a moonshot
Proving a cancer-screening test works requires enormous clinical trials — following hundreds of thousands of people for years. That costs far more than early revenue brings in.
GRAIL funds this from the cash it received when Illumina (the gene-sequencing giant that had acquired and then was forced to divest it) spun it off as an independent company in 2024. Like Moderna's COVID war chest, that reserve buys time — but every year of heavy losses draws it down.
Wall Street calls this
Cash burn / runway
GRAIL isn't about to vanish — it has a cushion. The question is whether it reaches FDA approval and insurance coverage *before* the reserve runs thin and it must raise money on tough terms.
Operating loss · fiscal year 2025
−$562
M
About 4× the year's revenue — the cost of running giant clinical studies and a national lab while the market is still being built. Funded from the cash GRAIL received at its spin-off from Illumina.
Source · 10-K · Consolidated Statements of Operations · FY2025 · Filed Mar 12, 2026
⚠
Funded, burning hard
A loss ~4× revenue, funded by a spin-off cash cushion. Not a near-term cash crisis — but a race to reach approval and coverage before the reserve thins.
You just finished
Chapter 2 · FINANCIAL HEALTH
Burning Big, Funded by the Spin
you now read: real cash left over (free cash flow)